Improvements At Neos Therapeutics Aren’t Reflected In The Share Price

  • The company’s revenues are growing at 40% while the share price is lingering.
  • The revenue growth has also brought a remarkable margin expansion in both gross and operating margins.
  • Cash outflows have been reduced significantly as a result and are likely to diminish further.

Source: Improvements At Neos Therapeutics Aren’t Reflected In The Share Price – Neos Therapeutics, Inc. (NASDAQ:NEOS) | Seeking Alpha